HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: CJN.03580708v1 4/3/630    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bradbury, B. D. Articles by Critchlow, C. W. Search for Related Content PubMed PubMed Citation Articles by Bradbury, B. D. Articles by Critchlow, C. W.

Effect of Epoetin Alfa Dose Changes on Hemoglobin and Mortality in Hemodialysis Patients with Hemoglobin Levels Persistently below 11 g/dL

Brian D. Bradbury^*, Mark D. Danese, Michelle Gleeson, and Cathy W. Critchlow^*

^* Department of Biostatistics and Epidemiology, Amgen, Inc., Thousand Oaks, California; and Outcomes Insights, Inc., Newbury Park, California

Correspondence: Brian D. Bradbury, DSc, MA, Department of Biostatistics and Epidemiology, Amgen, Inc., Thousand Oaks, CA 41984; Phone: 805-313-4343; Fax: 805-447-1984; E-mail: bradbury{at}amgen.com

Background and objectives: The mortality risk associated with attempting to raise hemoglobin (Hb) levels by increasing Epoetin alfa (EPO) doses in hemodialysis patients with persistently low Hb remains poorly understood.

Design, setting, participants, & measurements. We included hemodialysis patients from a large dialysis provider between July 2000 and June 2001 who had EPO dose and Hb data for 6 consecutive months, and a mean Hb <11 g/dl in months 4 to 6 (sub-11 period). We identify predictors of EPO dose changes during the sub-11 period; evaluate the proportion of patients achieving a Hb 11 g/dl after the sub-11 period by dose-change categories; and evaluate the association between EPO dose changes and mortality risk.

Results: Patients were more likely to receive greater EPO dose increases if they had lower EPO doses, higher Hb levels, or were recently hospitalized. Greater EPO dose increases elevated the likelihood of achieving an Hb 11 g/dl in the subsequent 3 mo. Larger EPO dose changes over the sub-11 period were not associated with an elevated mortality risk, but having an Hb <9 g/dl at the end of that period independent of dose change was associated with mortality risk. We found that patients receiving larger dose changes and whose resulting Hb level remained <9.5 g/dl at the end of the 3 mo were at elevated mortality risk.

Conclusions: In patients with persistently low Hb levels, mortality risk was strongly associated with the patient's ability to achieve a hematopoietic response rather than the magnitude of EPO dose titrations.

This article has been cited by other articles:

				A. K. Singh, J. Himmelfarb, and L. A. Szczech Resolved: Targeting a Higher Hemoglobin Is Associated with Greater Risk in Patients with CKD Anemia: Pro J. Am. Soc. Nephrol., July 1, 2009; 20(7): 1436 - 1443. [Abstract] [Full Text] [PDF]